ASCO 2026 Day 2 (May 30) Roundup — Peptide-and-Conjugate Oncology Slate Continues; Major June 1 Readouts Ahead (Bicycle Duravelo-2, Mayo TPIV200, Telix ProstACT)
ASCO 2026 Day 2 in Chicago continued the meeting's peptide-and-targeted-conjugate oncology programming. Saturday May 30 brought the Immutep eftilagimod alfa survival pooled analysis and the ImPact Biotech padeliporfin VTP pancreatic data, alongside the Bicycle Therapeutics zelenectide pevedotin dose-optimization poster (Abstract 4567, May 31) approaching. The meeting's heaviest peptide-mechanism day is Monday June 1: Bicycle Duravelo-2 zelenectide pevedotin + pembrolizumab oral presentation in 1L urothelial (Abstract 4516, 8:30 AM CT); Mayo Clinic TPIV200 folate-receptor peptide vaccine in triple-negative breast cancer (Abstract 536, 1:30 PM CT); Telix ProstACT PSMA radioligand Phase 3 Part 1; Sapience lucicebtide GBM poster. The Corbus CRB-701 Nectin-4 ADC data (42.9% OPSCC / 34.4% cervical) landed Friday May 29. The targeted-conjugate categories — Nectin-4, PSMA, B7-H3, FAP, SSTR2 — remain the densest peptide-adjacent oncology competition, with the bulk of definitive readouts concentrated in the meeting's back half through June 2.